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Background: The 6-min walking test (6MWT) is widely used to assess exercise tolerance in
patients with chronic obstructive pulmonary disease (COPD). Given the prognostic significance
of the 6MWT, it is important to identify why some COPD patients perform poorly in terms of this
outcome. We aimed to identify clinical determinants of a poor 6-min walking distance
(<350 m) in patients with COPD.
Methods: 1795 individuals with a diagnosis of COPD underwent spirometry; bio-electrical
impedance analysis; low-dose computed tomography scans of the chest; 6MWT; ATS-DLD co-
morbidity questionnaire; Center for Epidemiologic Studies of Depression Scale; COPD-specific
St Georges Respiratory Questionnaire; modified Medical Research Council (mMRC) dyspnea
scale as part of the baseline assessment of the Evaluation of COPD Longitudinally to Identify
Predictive Surrogate Endpoints (ECLIPSE) study.r ClinicalTrials.gov with identifier NCT00292552.
ionary of Program Development Centre, Ciro, a centre of excellence for chronic organ failure,
herlands. Tel./fax: þ31 475 587 600/666.
teion.nl (M.A. Spruit).
9 Elsevier Ltd. All rights reserved.
850 M.A. Spruit et al.Results: Patients with COPD have significant differences in performance in the 6MWT even
after stratification for GOLD stages. Moreover, severe airflow limitation by GOLD stage, degree
of emphysema by CT, oxygen use during/after the 6MWT, presence of depressive symptoms
and moderate to severe symptoms of dyspnea (mMRC grade 2) are significant clinical deter-
minants of poor 6MWD performance (<350 m).
Conclusions: The determinants of poor 6MWD are complex and depend on both physical
(both pulmonary and non-pulmonary factors) and psychological factors as evaluated from
a large multinational cohort of well-characterised patients with clinically stable moderate
to very severe COPD.
ª 2009 Elsevier Ltd. All rights reserved.Background
An impaired exercise tolerance is a cardinal clinical feature
in chronic obstructive pulmonary disease (COPD), which
cannot be confidently predicted from conventional
descriptors of a COPD patient such as age, gender, forced
expiratory volume in the first second (FEV1) and body mass
index (BMI).1 For these reasons, it is essential to measure
the patient’s exercise tolerance.
The 6-min walking test (6MWT) is a practical, relatively
simple test which has gained importance in evaluating the
functional status of patients with COPD.2 The test measures
the distance walked with maximal intensity,3 which better
reflects the patient’s functional exercise level for daily
physical activities than do conventional lung function
outcomes.4,5
The 6MWT is widely used in pulmonary rehabilitation
programs6 and in the evaluation of pharmacological and
non-pharmacological treatments for COPD.7e11 Indeed,
6MWT is recommended by the ATS/ERS as an important
outcome measure in clinical trials.12 Moreover, the 6MWT
has been shown to predict mortality in patients with clini-
cally stable COPD.4,13,14 Indeed, walking distances <350 m
on the 6MWT were associated with a significantly increased
mortality.4 In addition, the rate of decline in 6-min walking
distance (6MWD) over time has been shown to continue in
patients with severe COPD who cease to have significant
changes in FEV1
15 suggesting that the 6MWD can be used to
follow a patient’s worsening over time.
Given the prognostic significance of the 6MWT, it is
important to identify why some COPD patients perform
poorly in terms of this outcome. Many factors can influence
6MWD in COPD including gender,16 body composition,17 the
degree of airflow limitation,18 the degree of emphysema19
and the rate of acute COPD exacerbations.20 Moreover,
perceptions of poor health (i.e., the degree of daily dysp-
nea,21 emotional status22 and health status23) correlate with
6MWD in COPD. Thus, the 6MWD seems to be an integrative
test that reflects the physical, psychological and emotional
capabilities of patients with moderate to severe COPD.
To date, it remains unknown whether and to what extent
the above mentioned outcomes are interrelated in COPD.
Therefore, with the large and comprehensive cohort of the
Evaluation of COPD Longitudinally to Identify Predictive
Surrogate Endpoints (ECLIPSE) study, we explored the
importance of these factors relating to impairment of self-
paced exercise performance together in a single study.
Identifying clinical determinants of poor 6MWD may allowclinicians to better monitor and ameliorate impaired
functional capacity in patients with COPD.
Methods
The current data are derived from the baseline assessments
in the ECLIPSE study. The aims and operational aspects of the
ECLIPSE cohort have been described elsewhere.24 In brief,
individuals (age: 40e75 years) were recruited to the study if
they had a smoking history of>10 pack-years and a diagnosis
of COPD.25 All subjects performed baseline post-bronchodi-
lator spirometry and the FEV1% predicted was calculated.
26
Body composition
Height (cm) and body weight (kg) were measured. Subjects
also underwent bio-electrical impedance analysis (Bodystat
1500). Fat-free mass index was calculated using disease-
specific equations.27
Computed tomography
Low-dose computed tomography (CT) scans of the chest
(120 kVp, 40 mA, 1 or 1.25 mm slice thickness at full inspi-
ration) were obtained to exclude non-COPD-related disease
and to evaluate the severity and distribution of emphysema.
The CT scans were evaluated centrally at the imaging unit at
the University of British Columbia, Vancouver. The extent of
emphysema was independently scored by 2 radiologists who
were blind to the individual’s lung function. Emphysema was
reported as trivial, mild, moderate, and severe/very severe
if it affected <5%, 5e25%, 25e50%, >50% of the lungs,
respectively. A consensus reading was obtained when there
was a difference of more than one emphysema category
between the two observers. Otherwise, the average of the
two readings was used in the analysis.
Six-minute walk test
The 6-min walk test was performed indoors, along a flat,
straight, 30 m walking course supervised by a well-trained
researcher according to the ATS guidelines.2 A practice
6MWT was not completed. Patients were encouraged every
minute of the 6MWT using two phrases: ‘‘You are doing
well’’ or ‘‘Keep up the good work’’. Patients were allowed
to stop and rest during the test, but were instructed to
resume walking as soon as they felt able to do so. Patients
Determinants of poor 6MWD in COPD 851were asked to grade their shortness of breath and then
their level of fatigue using a modified Borg scale specific for
each at the beginning and at the end of the test.
Resting transcutaneous oxygen saturation was obtained
before and after the 6MWT. Oxygen saturation before the
6MWT and the use of oxygen during and/or after the 6MWT
was registered as possible determinants.
ATS respiratory questionnaire
Presence of self-reported cardiovascular co-morbidity was
determined using the ATS-DLD questionnaire,28 which was
updated for the purpose of this study. An affirmative
answer to one or more ‘‘heart trouble’’ questions (i.e., high
blood pressure, angina, heart attack/myocardial infarction,
stroke, heart failure, arrhythmia) was used as an affirma-
tive for presence of cardiovascular co-morbidity. Presence
of cardiovascular co-morbidity was examined as a possible
determinant.
Depression questionnaire
All patients completed the 20-items, self-administered
Center for Epidemiologic Studies of Depression Scale (CES-D)
to assess the presence of depressive symptoms.29 A total
CES-D score can range from 0 to 60 points. Binary categories
of respondents were created for this study using a generally
accepted cut-off of 16 points indicative of a high load of
depressive symptoms.29
Health status and mMRC dyspnea assessment
Health Status was assessed with the COPD-specific St
Georges Respiratory Questionnaire (SGRQ-C).30 The SGRQ-C
total score and the SGRQ-C activity domain were used for
the present analyses. In addition, dyspnea was assessed by
the self-administrated modified Medical Research Council
(mMRC) dyspnea scale.31
BODE index
The BODE index, a simple multidimensional grading system
which identifies prognostically different patient subgroups,
was determined using the algorithm proposed by Celli
et al.32 The BODE index was calculated as a characterizing
variable and was not examined as a possible determinant as
the index itself contains 6MWD as a component.
Statistics
Between-group comparisons were conducted by analysis of
variance and CochraneManteleHaenszel tests for contin-
uous and categorical assessments, respectively. Logistic
regression (with stepwise selection to determine model
covariates) assessed individual predictors of poor walking
distance (<350 m). The model was adjusted for age,
height, weight, gender, and country which were assumed to
be confounding variables. Model fit was evaluated by the
HosmereLemeshow goodness of fit test, examination of
model residuals, and investigation of possible interactions.
The confidence interval for area under receiver operatingcharacteristic curve (AUC ROC) was computed by the
method of DeLong.33 Sensitivity and specificity were
reported from the point on the ROC curve with the shortest
distance from the upper left corner (0,1).
Results
Characteristics
Of a total of 2747 participants (COPD patients and (non-)
smoking controls) enrolled into the ECLIPSE study,24 1795
patients with clinically stable COPD (63% men) from 12
countries completed the baseline 6MWT and were included
in the current study. Patients generally had moderate to very
severe COPD, a normal BMI, and an impaired health status
(Table 1). Moreover, 27% of the patients with COPD had
a high level of depressive symptoms (CES-D scale 16
points); 54% scored grade 2 or higher on the mMRC; and 54%
reported the presence of cardiovascular disease(s).
Characteristics of patients with poor 6MWD
743 patients (41%) had a 6MWD <350 m (mean: 256  73 m)
while the remaining 1052patients hada 6MWD350m (mean:
451  81 m). The group of patients with a 6MWD <350 m had
a higher proportion of women (41% vs. 34%); hospitalized
exacerbations (12% vs. 6%); very severe emphysema (>50%
emphysema by consensus radiologist read) (42% vs. 28%;
Fig. 1); possible depression (37% vs. 20%); mMRC dyspnea
grades of 2 or higher (77% vs. 38%); patient-reported cardio-
vascular disease(s) (59% vs. 50%); and oxygen users during
6MWT (16% vs. 3%) than was seen in subjects able to walk
further (Table 1). Additionally, patients with a 6MWD<350 m
generally had more severe airflow limitation (GOLD Stage IV:
23% vs. 7%; Table 1, Fig. 2) and worse health status (60 vs.
43 points on total SGRQ-C; and 77 vs. 55 points on the Activity
domain of SGRQ-C). Comparable differences were still found
between patients with 6MWD <350 m and 350 m for most
outcomes after stratification for GOLD stages (Table 2).
Determinants of poor 6MWD
From the logistic regression analysis, GOLD stage 4 patients
had a higher adjusted odds ratio for a poor 6MWD (<350 m)
than GOLD stage 2 patients, OR 1.91 (95% CI 1.20e3.03),
pZ 0.006. Additionally, oxygen users during/after the 6MWT
had an approximately doubling of risk of having a poor 6MWD
than COPDpatientswithout the use of oxygen, OR 2.16 (1.34e
3.47), pZ 0.002. Patients with mild emphysema or severe to
very severe emphysema had a higher adjusted odds ratio for
having a poor 6MWD than patients with trivial emphysema, OR
1.56 (1.07e2.27),pZ0.020;and1.89 (1.29e2.78),pZ0.001,
respectively. Finally, amMRCdyspnea grade of 2 or higher (OR
2.24 (1.70e2.95), p < 0.001), a CES-D score of 16 points of
higher (OR 1.51 (1.14e1.99), p Z 0.004), lower inspiratory
capacity (OR 0.97 (0.96e0.99), p< 0.001) and worse (higher)
scores on the SGRQ-C Activity domain (OR 1.03 (1.02, 1.03),
p< 0.001)werealso independentpredictorsofapoor6MWDin
the present sample. The presence of patient-reported
cardiovascular disease and a history of prior hospitalized
exacerbation did not affect the odds of poor 6MWD (Table 3).
Table 1 Patient characteristics.
All patients <350 m walked 350 m walked p-value
Patients 1795 743 1052
Age yrs 63  7 64  7 63  7 <0.001
Male 1135 (63%) 439 (59%) 696 (66%) 0.002
BMI kg/m2 26  6 27  6 26  5 <0.001
<21 264 (15%) 115 (15%) 149 (14%)
21e30 1135 (63%) 417 (56%) 718 (68%)
>30 396 (22%) 211 (28%) 185 (18%)
FFMI kg/m2 17  3 17  3 17  3 NS
Prior hospitalized exacerbations 157 (9%) 91 (12%) 66 (6%) <0.001
CVD by patient report 969 (54%) 439 (59%) 530 (50%) <0.001
FEV1 L 1.33  0.52 1.14  0.47 1.47  0.50 <0.001
GOLD Stage <0.001
Stage II 787 (44%) 228 (31%) 559 (53%)
Stage III 765 (43%) 346 (47%) 419 (40%)
Stage IV 243 (14%) 169 (23%) 74 (7%)
Inspiratory capacity L 2.25  0.73 2.00  0.69 2.42  0.71 <0.001
Extent of emphysema <0.001
<5% 460 (26%) 151 (20%) 309 (29%)
5e<25% 378 (21%) 143 (19%) 235 (22%)
25e<50% 350 (19%) 137 (18%) 213 (20%)
50e>75% 607 (34%) 312 (42%) 295 (28%)
mMRC mean score 1.7  1.1 2.2  1.0 1.3  0.9 <0.001
2 965 (54%) 570 (77%) 395 (38%) <0.001
SGRQ-C Total Score 50  20 60  18 43  19 <0.001
SGRQ-C Activity Score 64  25 77  20 55  24 <0.001
CES-D Score 11.7  9.3 14.2  9.8 9.9  8.5 <0.001
16 489 (27%) 278 (37%) 211 (20%) <0.001
6MWD m 370  124 256  73 451  81 <0.001
BODE Index 3.2  2.1 4.8  1.9 2.0  1.4 <0.001
Patients requiring
oxygen during/after 6MWT
154 (9%) 119 (16%) 35 (3%) <0.001
m Z meters; 6MWD Z 6 min walk distance; BMI Z body mass index; FEV1 Z forced expiratory volume in 1 s; CVD Z cardiovascular
disease; GOLDZ Global Initiative for Chronic Obstructive Lung Disease; mMRCZ modified Medical Research Council Scale for dyspnea;
CES-DZ Center for Epidemiologic Studies Despression Scale; BODE IndexZ Airflow Obstruction, Dyspnea, and Exercise Capacity Index;
NSZ not significant. History of hospitalized exacerbation are those COPD exacerbations requiring hospitalization in the 12 months prior
to patient entry in the ECLIPSE study as reported by the patient. All values are n (%) or mean  standard deviation. yp values for
difference between patients walking<350 m and 350 m.
852 M.A. Spruit et al.The patients who used oxygen during/after the 6MWT
had significantly different characteristics than patients who
did not use oxygen during/after the 6MWT (Table 4).
Receiver operating characteristic curve
The area under the receiver operating characteristic (ROC)
curve for the current model was 0.851 (0.834e0.869), with
a sensitivity of 77.9% and a specificity of 77.5%.
Discussion
This large multinational study had two important findings:
first, it showed that patients with COPD have significantdifferences in performance in the 6MWD even after stratifi-
cation for GOLD stages. Second, we determined that the
following covariates are significant clinical determinants of
poor 6MWD performance (<350 m): severe airflow limitation
by GOLD stage, degree of emphysema by CT, oxygen use
during/after the 6MWT, presence of depressive symptoms and
moderate to severe symptoms of dyspnea (mMRC grade2).
Although poor 6MWD can be differentiated by increasing
severity of GOLD stage (Table 3), there was considerable
variation in the proportion of patients in each GOLD stage
with a 6MWD <350 m or 350 m. For example, 29% of the
GOLD stage 2 patients had a 6MWD <350 m, while 30% of
the GOLD stage 4 patients had a 6MWD 350 m (Fig. 2). In
addition, the identified clinical determinants from the
regression model appear to be the same variables
Figure 1 Histogram distribution of 6MWD by extent of emphysema. The bold line marks the<350 m walking distance threshold. The
difference in the proportion of patients who walked <350 m between emphysema stages was statistically significant (p < 0.001).
Determinants of poor 6MWD in COPD 853differentiating the <350 m vs. 350 m walking groups in
each GOLD stage (Table 2). These results suggest that the
degree of airflow limitation only partially explains the
variance in 6MWD in patients with moderate to very severe
COPD, a finding previously suggested by other authors.34,35
In fact, we found a similar number of pulmonary and non-
pulmonary factors associated with a reduced 6MWT
performance. Some of the non-pulmonary factors (mMRC
dyspnea and depression scale) were more important orFigure 2 Histogram distribution of 6MWD by GOLD stage. The
difference in the proportion of patients who walked <350 m betwconsistently associated with the distance walked compared
to the pulmonary parameters investigated (inspiratory
capacity and extent of emphysema). A decline in resting
inspiratory capacity (incremental change of 200 ml) and the
extent of emphysema only mildly to moderately increased
the odds of having poor 6MWD, respectively (Table 3).
Meanwhile, COPD patients with poor 6MWD had a worse
mean SGRQ-C Activity score; a higher percentage of
patients with symptoms of dyspnea (mMRC  2) andbold line marks the <350 m walking distance threshold. The
een GOLD stages was statistically significant (p < 0.001).
Table 2 Patient characteristics by GOLD Stage and 6MWD performance.
Stage II Stage III Stage IV
<350 m 350 m <350 m 350 m <350 m 350 m
Patients 228 559 346 419 169 74
Age yrs 64  7 63  7 65  7 63  7 63  7 61  7
Male 119 (52%) 337 (60%) 202 (58%) 303 (72%) 118 (70%) 56 (76%)
BMI kg/m2 29  6 27  5 27  6 25  5 25  6 25  5
<21 20 (9%) 59 (11%) 53 (15%) 76 (18%) 42 (25%) 14 (19%)
21e30 119 (52%) 390 (70%) 200 (58%) 277 (66%) 98 (58%) 51 (69%)
>30 89 (39%) 110 (20%) 93 (27%) 66 (16%) 29 (17%) 9 (12%)
FFMI, kg/m2 18  3 17  3 17  3 17  3 16  3 16  2
Prior hospitalized
exacerbations
15 (7%) 21 (4%) 46 (13%) 38 (9%) 30 (18%) 7 (9%)
CVD by patient report 150 (66%) 298 (53%) 198 (57%) 195 (47%) 91 (54%) 37 (50%)
FEV1 L 1.62  0.44 1.78  0.45 1.04  0.26 1.18  0.26 0.70  0.17 0.78  0.15
Inspiratory Capacity L 2.39  0.77 2.57  0.74 1.90  0.55 2.31  0.64 1.69  0.60 1.96  0.55
Extent of Emphysema
<5% 76 (33%) 222 (40%) 64 (18%) 76 (18%) 11 (7%) 11 (15%)
5e<25% 69 (30%) 135 (24%) 56 (16%) 90 (21%) 18 (11%) 10 (14%)
25e<50% 41 (18%) 113 (20%) 64 (18%) 86 (21%) 32 (19%) 14 (19%)
50e>75% 42 (18%) 89 (16%) 162 (47%) 167 (40%) 108 (64%) 39 (53%)
mMRC mean score 1.9  1.0 1.1  0.9 2.3  1.0 1.5  0.9 2.5  1.0 2.0  0.8
2 152 (67%) 163 (29%) 277 (80%) 178 (42%) 141 (83%) 54 (73%)
SGRQ-C Activity Score 69  22 48  24 79  19 61  22 85  16 72  17
CES-D Score 14  10 10  9 15  10 10  8 14  10 10  8
16 82 (36%) 109 (19%) 135 (39%) 87 (21%) 61 (36%) 15 (20%)
6MWD m 282  59 460  84 252  74 442  73 229  78 431  87
BODE Index 3.0  1.3 1.1  0.9 5.3  1.4 3.0  1.0 6.4  1.4 4.2  0.9
Patients requiring
oxygen during/
after 6MWT
11 (5%) 12 (2%) 52 (15%) 17 (4%) 56 (33%) 6 (8%)
m Z meters; 6MWD Z 6 min walk distance; BMI Z body mass index; FEV1 Z forced expiratory volume in 1 s; CVD Z cardiovascular
disease; GOLDZ Global Initiative for Chronic Obstructive Lung Disease; mMRCZ modified Medical Research Council Scale for dyspnea;
CES-DZ Center for Epidemiologic Studies Depression Scale; BODE IndexZ Body Mass Index, Airflow Obstruction, Dyspnea, and Exercise
Capacity Index; NSZ not significant. History of hospitalized exacerbation are those COPD exacerbations requiring hospitalization in the
12 months prior to patient entry in the ECLIPSE study as reported by the patient. All values are n (%) or mean  standard deviation.
yp values for difference between patients walking <350 m and 350.
854 M.A. Spruit et al.depressive symptoms (CES-D  16) (Table 1) which
remained after stratification for GOLD stages (Table 2) and
after correction for gender, age, body weight and country
(Table 3). All three self-perceived measures identified an
increased likelihood of having a poor 6MWD (Table 3).
Therefore, it seems reasonable to conclude that the pres-
ence of poor 6MWD is multifactorial and that non-pulmo-
nary outcomes should be considered to explain the variance
in 6MWD in patients with moderate to very severe COPD.
Surprisingly, fat-free mass (FFM) index, hospitalized COPD
exacerbations (self-reported in the previous year before
enrolment in the study), and presence of cardiovascular
disease did not differentiate themselves as determinants of
a poor 6MWD which is somewhat contrary to the published
literature. However, there are several possible reasons which
may explain these findings. In the present study themean FFM
index was identical between COPD patients with and without
poor 6MWD (Table 1) and ultimately FFM index was not
selected by the model as a determinant of poor 6MWD, aftercorrection for confounding variables (Table 3). In contrast,
Ischaki and colleagues reported a positive correlation
between6MWDandFFM index inpatientswithCOPD, however
this was demonstrated without correction for confounding
variables like weight, gender, age and the degree of airflow
limitation.17 Addition of these variables in the model along
with the inclusion of a number of other factors which were
relatively more significant to poor 6MWD explain why FFM
indexwas not selected by the stepwise regressionmodel. Also
in our study, a higher proportion of the COPD patients with
poor 6MWD had self-reported hospitalizations for COPD
exacerbations (Table 1), however previous hospitalized
exacerbations did not reach statistical significance as
a determinant of poor walk distance (Table 3). We know from
the literature that COPD patients with a lower 6MWD are
more likely to have exacerbations following pulmonary reha-
bilitation, and that acute COPD exacerbations are associated
with clinically relevant reductions in 6MWD.20,36,37 The reason
that statistical significance was not achieved in the present
Table 3 Odds ratios between subject characteristics and
poor 6MWT performance (<350 m) e Logistic Regression.
<350 m walked
OR (95% CI) p-value
GOLD Staging
Stage II 1.00
Stage III 1.10 (0.82, 1.48) NS
Stage IV 1.91 (1.20, 3.03) 0.006
Inspiratory Capacity
(per 200 ml)
0.97 (0.96, 0.99) <0.001
Oxygen during/after walk
No 1.00
Yes 2.16 (1.34, 3.47) 0.002
Extent of Emphysema
<5% 1.00
5e<25% 1.56 (1.07, 2.27) 0.020
25e<50% 1.35 (0.91, 2.00) NS
50e>75% 1.89 (1.29, 2.78) 0.001
Cardiovascular disease
No 1.00
Yes 1.11 (0.86, 1.43) NS
History of Hospitalized Exacerbation
No 1.00
Yes 1.47 (0.97, 2.25) NS
mMRC
<2 1.00
2 2.24 (1.70, 2.95) <0.001
CES-D
<16 1.00
16 1.51 (1.14, 1.99) 0.004
SGRQ-C activity domain 1.03 (1.02, 1.03) <0.001
ORZ odds ratio (adjusted for country, age, height, weight, and
gender); 95% CI Z 95% confidence interval; NS Z not signifi-
cant. The < 350 m odds ratio reflects the odds of walking
<350 m vs. 350 m. History of hospitalized exacerbation are
those COPD exacerbations requiring hospitalization in the 12
months prior to patient entry in the ECLIPSE study as reported
by the patient.
Table 4 Characteristics of patients with or without
oxygen during/after 6MWT.
No
oxygen
Oxygen
during/
after 6MWT
p-valuey
Patients 1641 154
Age yrs 63  7 65  6 <0.001
Male 1040 (63%) 95 (62%) 0.678
BMI kg/m2 26  5 27  6 0.053
FFMI kg/m2 17  3 17  3 0.657
Prior hospitalized
exacerbations
131 (8%) 26 (17%) <0.001
CVD by patient report 877 (53%) 92 (60%) 0.134
FEV1 L 1.37  0.51 0.94  0.40 <0.001
GOLD stage <0.001
Stage II 764 (47%) 23 (15%)
Stage III 696 (42%) 69 (45%)
Stage IV 181 (11%) 62 (40%)
Inspiratory capacity L 2.29  0.72 1.83  0.68 <0.001
Extent of emphysema <0.001
<5% 454 (28%) 6 (4%)
5e<25% 354 (22%) 24 (16%)
25e<50% 317 (19%) 33 (21%)
50e>75% 516 (31%) 91 (59%)
mMRC mean score 1.6  1.0 2.2  1.0 <0.001
 2 852 (52%) 113 (73%) <0.001
SGRQ-C total score 49  20 61  15 <0.001
SGRQ-C activity score 62  25 82  17 <0.001
CES-D score 11.5  9.3 13.8  9.2 0.003
16 434 (26%) 55 (36%) 0.014
6MWD m 379  120 271  116 <0.001
BODE Index 3.0  2.1 5.1  2.1 <0.001
Determinants of poor 6MWD in COPD 855study may have been due to adjustments made for con-
founding variables in the model, which like patient body
weight, have been shown to be clinical determinants of
hospitalized acute COPD exacerbations.36 Moreover, in our
study, only patients with clinically stable COPD were eligible
to participate;24 and the exacerbation-related hospitaliza-
tionswere based solely onpatient recall of events 1-year prior
to beginning the ECLIPSE study. In a similar fashion to hospi-
talized COPD exacerbations, self-reported cardiovascular
diseases was not a significant determinant of a poor 6WMD,
although itwas commoner inpatientswithpoor6MWD inGOLD
stages 2 and 3 (p  003), but not in GOLD stage 4 patients
(pZ 0.581). As before, this may be explained in part by the
ECLIPSE study requirement for ‘‘stable’’ co-morbid conditions
at the start of study participation.24
Taken together, this report has several strengths. It
includes a large, multinational population of patients withdifferent levels of disease severity, and a high proportion of
women. The simultaneous analysis of several factors
previously reported to affect the 6MWT allowed to deter-
mine the interrelation among them and selection of seven
distinctive ones. The identified predictors were shown to
demonstrate good discrimination between COPD patients
with and without a poor 6MWD (area under the ROC curve of
0.851). Although very good, it may be speculated that some
other factors not included in our model could even further
improve its discriminative power (e.g., measurement of
daily physical activity levels,5 systemic biomarkers of bio-
logical aging38 and systemic inflammation39).
A 6MWD<350mwas used as a poorwalk distance threshold
in the present study based upon previous work demonstrating
association with mortality in patients with COPD.4 Neverthe-
less, it will still be important to replicate these outcome-
based findings from the 3-year prospective ECLIPSE cohort
data. Moreover, it will be of clinical importance to assess
whether6MWDwill declineover timeandwhetherand towhat
extent clinical predictors of decline selected in this analysis
would be of value during the 3 years of follow-up of the
ECLIPSE cohort. This information is of critical value to better
assess the 6MWT as a potential outcome to be measured in
pharmacologic intervention studies. Its association to the
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856 M.A. Spruit et al.systemic repercussion of the disease (cardio-pulmonary,
perception and psychological impact) and mortality should
complement spirometry, which to date has been the only
important parameter to modify in COPD.
To conclude, the determinants of poor 6MWD are complex
and depend on both physical (both pulmonary and non-
pulmonary factors) and psychological factors as evaluated
from a large multinational cohort of well-characterised
patientswith clinically stablemoderate to very severeCOPD.
This could in time result in better non-pharmacological as
well as pharmacological management of patients with COPD.
Indeed, poor 6MWD may improve in patients with moderate
to very severe COPD without clinically relevant changes in
pulmonary function.8 So, from a patient management
perspective, we hypothesize that GOLD stage 2 patients with
a poor 6MWD should be evaluated more critically to deter-
mine whether pharmacological or non-pharmacological
treatment interventions are likely to be helpful. It seems
that this group may be more likely to benefit from interven-
tions targeting extra-pulmonary manifestations of COPD as
opposed to interventions targeting pulmonary function.
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